<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended SEPTEMBER 30, 1997
-------------------------------------------------
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
---------------------- -----------------------
Commission file number 0-26206
---------------------------------------------------------
NORLAND MEDICAL SYSTEMS, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 06-1387931
- ------------------------------- ------------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
106 CORPORATE PARK DRIVE, SUITE 106
WHITE PLAINS, NEW YORK 10604
- --------------------------------------------------------------------------------
(Address of principal executive offices)
(Zip Code)
(914) 694-2285
- --------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
- --------------------------------------------------------------------------------
(Former name, former address and former fiscal year, if changed since last
report)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes X No
--- ---
As of October 31, 1997, 7,162,531 shares of the registrant's Common Stock,
$0.0005 par value, were outstanding.
-1-
<PAGE>
NORLAND MEDICAL SYSTEMS, INC.
TABLE OF CONTENTS FOR FORM 10-Q
Page
----
Title Page....................................................................1
Document Table of Contents....................................................2
PART I FINANCIAL INFORMATION................................................3
Item 1. Condensed Consolidated Financial Statements..........................3
Condensed Consolidated Balance Sheets................................3
Condensed Consolidated Statements of Operations......................4
Condensed Consolidated Statements of Changes in Stockholders' Equity.5
Condensed Consolidated Statements of Cash Flows......................6
Notes to Condensed Consolidated Financial Statements.................7
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations...........................................13
PART II OTHER INFORMATION...................................................18
Item 1. Legal Proceedings...................................................18
Item 2. Changes in Securities...............................................19
Item 3. Defaults Upon Senior Securities.....................................19
Item 4. Submission of Matters to a Vote of Security Holders.................19
Item 5. Other Information...................................................20
Item 6. Exhibits and Reports on Form 8-K....................................20
Signatures...................................................................21
Exhibit Index................................................................22
-2-
<PAGE>
<TABLE>
<CAPTION>
PART I FINANCIAL INFORMATION
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NORLAND MEDICAL SYSTEMS, INC.
Condensed Consolidated Balance Sheets
(Unaudited) September 30, 1997 December 31, 1996
------------------ -----------------
ASSETS
<S> <C> <C>
Current assets:
Cash and cash equivalents $ 2,385,127 $ 8,133,468
Investment -- 1,949,039
Accounts receivable - trade, less allowance for
doubtful accounts of $250,000 at September 30,
1997 and $221,000 at December 31, 1996 13,615,546 9,182,488
Income taxes recoverable 161,907 794,285
Inventories, net 3,132,377 616,865
Officers' loans receivable 85,294 581,704
Deferred income taxes 2,434,205 --
Current portion of product development loan
receivable - affiliate -- 38,685
Prepaid expenses and other current assets 321,827 361,902
----------- -----------
Total current assets 22,136,283 21,658,436
----------- -----------
Demonstration systems inventory, net 75,393 1,234,848
Investment in Vitel, Inc 260,000 260,000
Property and equipment, net 703,898 406,375
Product development loan receivable - affiliate -- 251,100
Goodwill, net 10,205,399 3,183,961
Other intangible assets, net -- 3,248,658
----------- -----------
Total assets $33,380,973 $30,243,378
=========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of note payable $1,250,000 $ --
Accounts payable - Norland Corporation -- 2,220,816
Accounts payable - Stratec 164,153 714,127
Accounts payable - trade 1,640,610 81,416
Accrued expenses 3,557,159 706,154
----------- -----------
Total current liabilities 6,611,922 3,722,513
----------- -----------
Other liabilities:
Note payable, net of discount 14,279,344
Deferred income taxes 292,586
-----------
Total other liabilities 14,571,930
-----------
Stockholders' equity:
Common stock, par value of $0.0005 per share,
20,000,000 shares authorized, 7,155,031 and
6,904,781 shares issued at September 30, 1997
and December 31, 1996, respectively 3,578 3,452
Additional paid-in capital 22,195,686 22,158,170
Retained earnings (accumulated deficit) (10,002,143) 4,359,243
----------- -----------
Total stockholders' equity 12,197,121 26,520,865
----------- -----------
Total liabilities and stockholders' equity $33,380,973 $30,243,378
=========== ===========
</TABLE>
See accompanying notes to condensed consolidated financial statements.
-3-
<PAGE>
NORLAND MEDICAL SYSTEMS, INC.
Condensed Consolidated Statements of Operations
(Unaudited)
<TABLE>
<CAPTION>
For the Three Months Ended For the Nine Months Ended
---------------------------------------- -----------------------------------------
September 30, 1997 September 30, 1996 September 30, 1997 September 30, 1996
------------------ ------------------ ------------------ ------------------
<S> <C> <C> <C> <C>
Revenue $ 6,360,537 $8,066,882 $19,491,446 $20,234,288
Cost of revenue 2,980,956 5,414,587 10,412,167 13,210,628
------------ ---------- ----------- -----------
Gross profit 3,379,581 2,652,295 9,079,279 7,023,660
Sales and marketing expense 1,515,775 941,743 4,196,122 2,400,263
General and administrative expense 765,574 497,706 1,986,856 1,291,143
Research and development expense 165,502 94,596 353,289 200,931
In-process research and development
charge 7,900,000 -- 7,900,000 --
Other non-recurring charges 10,562,540 397,697 10,562,540 397,697
------------ ---------- ----------- -----------
Operating income (loss) (17,529,810) 720,553 (15,919,528) 2,733,626
Interest expense (66,096) 0 (66,096) 0
Interest income 75,764 146,782 326,238 560,480
------------ ---------- ----------- -----------
Income (loss) before taxes (17,520,142) 867,335 (15,659,386) 3,294,106
Provision (benefit) for income taxes (2,054,000) 352,000 (1,298,000) 1,337,459
------------ ---------- ----------- -----------
Net income (loss) $(15,466,142) $ 515,335 $(14,361,386) $ 1,956,647
============ ========== ============ ===========
Weighted average number of common
and common equivalent shares:
Primary 7,245,006 7,214,920 7,202,948 7,176,061
Fully diluted 7,191,218 7,261,504 7,193,309 7,203,390
Earnings (loss) per share:
Primary $ (2.13) $ 0.07 $ (1.99) $ 0.27
Fully diluted (2.15) 0.07 (2.00) 0.27
</TABLE>
See accompanying notes to condensed consolidated financial statements.
-4-
<PAGE>
NORLAND MEDICAL SYSTEMS, INC.
Condensed Consolidated Statements of Changes in Stockholders' Equity
For the Nine Months Ended September 30, 1997 and 1996
(Unaudited)
<TABLE>
<CAPTION>
Retained
Additional Earnings
Common Paid-In (Accumulated
Total Shares Stock Capital Deficit)
------------ --------- ------ ----------- ------------
<S> <C> <C> <C> <C> <C>
Balance as of
December 31, 1996 $ 26,520,865 6,904,781 $3,452 $22,158,170 $ 4,359,243
Issuance of shares for
stock options exercised 37,642 250,250 126 37,516 --
Net loss (14,361,386) -- -- -- (14,361,386)
------------ --------- ------ ----------- ------------
Balance as of
September 30, 1997 $ 12,197,121 7,155,031 $3,578 $22,195,686 $(10,002,143)
============ ========= ====== =========== ============
Balance as of
December 31, 1995 $ 20,520,846 6,000,000 $3,000 $18,349,813 $ 2,168,033
Issuance of shares for
stock options exercised 288 734,250 367 (79) --
Issuance of shares to acquire
Dove Medical Systems 3,311,519 161,538 81 3,311,438 --
Cost and expenses
directly related to the
stock offering (3,002) -- -- (3,002) --
Cash paid in lieu of fractional
shares on 3-for-2 stock split
on June 14, 1996 (164) (7) -- -- (164)
Net income 1,956,647 -- -- -- 1,956,647
------------ --------- ------ ----------- ------------
Balance as of
September 30, 1996 $ 25,786,134 6,895,781 $3,448 $21,658,170 $ 4,124,516
============ ========= ====== =========== ============
</TABLE>
See accompanying notes to condensed consolidated financial statements.
-5-
<PAGE>
NORLAND MEDICAL SYSTEMS, INC.
Condensed Consolidated Statements of Cash Flows
<TABLE>
<CAPTION>
(Unaudited) Nine Months Ended
September 30, 1997 September 30, 1996
Cash flows from operating activities:
<S> <C> <C>
Net income (loss) $(14,361,386) $ 1,956,647
Adjustments to reconcile net income (loss) to net cash
used in operating activities:
In-process research and development charge 7,900,000 --
Other non-recurring charges 10,562,540 397,697
Amortization expense 419,594 228,138
Depreciation expense 97,532 36,044
Gain on sale of investment (47,364) --
Provision for doubtful accounts receivable 29,000 70,000
Inventory obsolescence expense -- 30,000
Deferred income taxes (2,437,000) --
Changes in assets and liabilities net of the
effects from acquisitions:
Accounts receivable (4,462,058) (6,509,776)
Inventories (1,086,644) (469,992)
Prepaid expenses and other current assets 67,837 (665,607)
Accounts payable (4,176,523) 2,100,891
Accrued expenses 625,053 (80,058)
Recoverable income taxes 948,814 (1,392,660)
------------ -----------
Total adjustments 8,440,781 (6,255,323)
------------ -----------
Net cash used in
operating activities (5,920,605) (4,298,676)
------------ -----------
Cash flows from investing activities:
Purchase of Norland Corporation, net of cash acquired (2,017,509) --
Loans to officers (1,908,363) (1,108,754)
Repayments of loans to officers 2,404,773 --
Sale of investment 1,996,403 --
Product development loan to affiliate (252,261) (32,738)
Repayment of product development loan
to affiliate 32,046 --
Purchase of property and equipment (120,468) (316,615)
Payment for purchase of certain intangible assets
of Dove Medical Systems, net of cash acquired -- (3,432,937)
Investment in Vitel, Inc. -- (260,000)
------------ -----------
Net cash provided by (used in)
investing activities 134,621 (5,151,044)
------------ -----------
Cash flows from financing activities:
Proceeds from stock options exercised 37,643 288
Cost and expenses of issuance of common stock -- (3,002)
Cash paid for fractional share -- (164)
------------ -----------
Net cash provided by (used in)
financing activities 37,643 (2,878)
------------ -----------
Net decrease in cash (5,748,341) (9,452,598)
Cash at beginning of period 8,133,468 19,218,865
------------ -----------
Cash at end of period $ 2,385,127 $ 9,766,267
============ ===========
Non-cash investing and financing activities:
Note payable issued to acquire Norland
Corporation, net of discount $ 15,522,461 --
</TABLE>
See accompanying notes to condensed consolidated financial statements.
-6-
<PAGE>
NORLAND MEDICAL SYSTEMS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(1) BASIS OF PRESENTATION
The condensed consolidated financial statements of Norland Medical Systems, Inc.
(the "Company") presented herein, have been prepared pursuant to the rules of
the Securities and Exchange Commission for quarterly reports on Form 10-Q and do
not include all of the information and footnote disclosures required by
generally accepted accounting principles. These statements should be read in
conjunction with the audited financial statements and notes thereto for the year
ended December 31, 1996, and included in the Company's Form 10-K as filed with
the Securities and Exchange Commission on March 31, 1997 and amended by Form
10-K/A filed on July 10, 1997. The figures in these statements have been
restated to reflect the 3 for 2 stock split which was effective June 14, 1996.
The condensed consolidated financial statements included herein are unaudited
but, in the opinion of management, include all adjustments (consisting of
normal, recurring adjustments) necessary for a fair presentation of the
financial position, results of operations and cash flows for these interim
periods.
The results of operations for the three and nine months ended September 30, 1997
are not necessarily indicative of the results to be expected for the entire
fiscal year ending December 31, 1997.
(2) INVENTORIES
As of September 30, 1997, inventories consist of the following:
Raw materials, product kits,
spare parts and sub-assemblies $ 450,306
Work in progress 540,356
Rental systems, net of accumulated
amortization of $37,958 206,894
Finished goods 1,934,821
----------
$3,132,377
==========
Inventories are stated at the lower of cost or market; cost is determined
principally by the first-in, first-out method.
Systems used in the Company's short-term rental program are carried in inventory
at cost less amortization expense calculated on a straight-line basis over
thirty-six months.
-7-
<PAGE>
Notes to Condensed Consolidated Financial Statements, continued:
(3) DEMONSTRATION SYSTEMS INVENTORY
The Company maintains an inventory of demonstration systems used for marketing
and customer service purposes. Such systems are carried at the lower of cost or
net realizable value until the time of sale. From time to time, the Company may
judge it desirable for marketing purposes to provide a device to a prominent
scientist or research institution specializing in the study of bone disease. In
such cases, the Company will carry the device in demonstration systems inventory
at cost less amortization expense calculated on a straight-line basis over
thirty-six months.
(4) DOVE MEDICAL SYSTEMS
On April 2, 1996, the Company acquired all of the outstanding shares of Dove
Medical Systems (Dove) and a certain patent and other intangible assets owned by
the Dove majority shareholder and certain other investors. The Company paid
consideration of $6,911,529, consisting of $3,600,000 in cash and 161,538 shares
of the Company Common Stock valued at $3,311,529. The acquisition was accounted
for using the purchase method of accounting, and, accordingly, the purchase
price was allocated to the assets purchased and the liabilities assumed based on
the fair values at the date of acquisition. The excess purchase price over the
fair values of the net assets was $3,308,011 and was recorded as goodwill. In
accordance with the Company's accounting policy for intangible assets,
management evaluates on an ongoing basis the Company's ability to recover the
carrying value of its intangible assets. In response to the increasing
dominance of the peripheral bone densitometry market by DXA technology, the
Company initiated a plan in September 1997 to close Dove's Newbury Park
facility, write-off inventories and fixed assets and discontinue use of the Dove
technology and patent. In addition, management has estimated the future cash
flows expected to result from the use of the goodwill, patent and other
intangible assets associated with Dove and concluded that expected cash flows
will not enable the Company to recover any of the remaining carrying value. The
patent and intangible assets are not expected to have any future alternative
use. Therefore, the Company has taken a $6,188,143 charge for their write-off
that is included in the $9,000,000 non-recurring charge taken with respect to
Dove in the period ended September 30, 1997.
(5) ACQUISITION OF NORLAND CORPORATION
On September 11, 1997, the Company acquired Norland Corporation in a transaction
accounted for under the purchase method of accounting. The condensed
consolidated financial statements reflect the acquisition of all of the issued
and outstanding stock of Norland Corporation for $17.5 million from the date of
acquisition. The $17.5 million consideration consists of a $1,250,000 cash
payment made on September 11, 1997 and a $16,250,000 Purchase Note (the "Note")
bearing interest at the rate of 7% per annum which is payable quarterly
beginning September 30, 1997. A $1,250,000 portion of the Note principal is
payable in cash on March 11, 1998, and the remaining principal is due and
payable on September 11, 2002. The Company may prepay the Note at any time, pay
the principal
-8-
<PAGE>
Notes to Condensed Consolidated Financial Statements, continued:
(except for the $1,250,000 payment due March 11, 1998) with shares of Company
Common Stock valued at the time of payment and extend the September 11, 2002
maturity date by up to two years. The Note is collateralized by a pledge of the
shares of Norland Corporation. An additional purchase price of up to $2.5
million may be required based on the level of the Company's 1997 revenues to be
determined following the completion of the audit of the Company's financial
statements for the year ending December 31, 1997. For each full $1,000,000 of
1997 revenues above $32,000,000, the purchase price will be increased by
$312,500 (up to the maximum increase of $2.5 million). Any additional purchase
price would be paid by an additional note, the terms of which would be identical
to the Note except for the principal payment due March 11, 1998.
In accordance with Accounting Principals Board Opinion No. 21, "Interest on
Receivables and Payables", the Note has been fair valued as of September 11,
1997 using a market interest rate of 8.18%, which resulted in the establishment
of a $727,539 note discount that is being amortized using the effective interest
method over the Note's five year term. The purchase price has been allocated as
follows:
Purchase price, net of Note discount of $727,539 $16,772,461
Net liabilities assumed 210,790
In-process research and development charge (7,900,000)
Deferred income tax liability 295,381
Acquisition costs 859,767
-----------
Goodwill $10,238,399
===========
Acquisition costs are primarily legal, accounting and investment banking
fees, as well as certain settlement costs in connection with stockholder
litigation stemming from the acquisition (see Note 8), all of which are
directly related to the transaction. In connection with the acquisition of
Norland Corporation on September 11, 1997, certain research and development
projects acquired were not at a stage in which technological feasibility had
been achieved and were determined to have no alternative future use.
Accordingly, $7,900,000 of the purchase price was allocated to this
in-process research and development and expensed as a non-recurring charge in
the period ended September 30, 1997. The goodwill is being amortized using
the straight-line method over fifteen years. If any additional purchase
price is required, such amount, when determined, will be recorded as
additional goodwill.
-9-
<PAGE>
Notes to Condensed Consolidated Financial Statements, continued:
The following table reflects pro forma unaudited consolidated operating results
of the Company and Norland Corporation assuming the acquisition had been made as
of January 1, 1996:
Nine Months Ended Year Ended
September 30, 1997 December 31, 1996
------------------ -----------------
(Unaudited) (Unaudited)
Revenues $19,204,538 $24,958,654
Net income (loss) (8,100,000) 2,900,000
Earnings (loss) per share $ (1.12) $ 0.40
These unaudited pro forma results have been prepared for comparative purposes
only and include certain adjustments to give effect to amortization of the
goodwill and certain other adjustments, together with related income tax
effects, and excludes the write-off of in-process research and development. The
unaudited pro forma information is not necessarily indicative of either the
results of operations that would have occurred had the acquisition been made on
January 1, 1996 or that may occur in the future.
(6) OTHER NON-RECURRING CHARGES
The Company recorded other non-recurring charges in the quarter ended September
30, 1997 of $10,562,540 consisting of the following:
Reorganization of Dove Medical Systems $ 9,000,000
Inventory write-off 1,460,735
Costs to acquire ultrasound distribution rights 101,805
-----------
$10,562,540
In September 1997, the Company initiated a plan to reorganize its Dove Medical
Systems subsidiary including the closure of the Newbury Park facility and
write-off of inventories, fixed assets, goodwill, a patent and other intangible
assets, resulting in a $9,000,000 non-recurring charge (See Note 4). With the
acquisition of Norland Corporation, including its ongoing research and
development projects, management determined that the Company's inventory of bone
densitometry systems used for demonstration and customer service purposes had no
future value and recognized a $1,460,375 non-recurring charge for their
write-off. In August 1997, the Company acquired distribution rights to an
ultrasound product developed by IMRO, Inc.. A $101,805 non-recurring charge was
taken for costs incurred in connection with the selection of an ultrasound
product.
In the quarter ended September 30, 1996, the Company recorded a non-recurring
stock offering charge of $397,697, or 3 cents per share, in connection with a
withdrawn stock offering.
-10-
<PAGE>
Notes to Condensed Consolidated Financial Statements, continued:
(7) NET INCOME PER COMMON AND COMMON EQUIVALENT SHARE
Primary income (loss) per share is calculated by dividing net income (loss) by
the average shares of common stock and common stock equivalents outstanding
during the period. Common stock equivalents are stock options which have been
included using the treasury stock method only when their effect is dilutive.
(8) LITIGATION
A shareholder's class action and derivative complaint entitled IRWIN J. MILLER
V. REYNALD G. BONMATI ET. AL. DEFENDANTS, AND NORLAND MEDICAL SYSTEMS, INC.,
NOMINAL DEFENDANT was filed in the Court of Chancery of the State of Delaware on
August 1, 1997, against four members of the Company's Board of Directors (the
"Individual Defendants"), Norland Medical Systems B.V. ("NMS BV"), and the
Company. The action relates to the acquisition (the "Acquisition")
by the Company from NMS BV of all the outstanding stock of Norland Corporation.
The complaint alleged that the Individual Defendants breached their fiduciary
duties of loyalty, candor and care in connection with the Acquisition, and that
the Company's proxy statement relating to the Acquisition did not contain full
and fair disclosure with respect to the Acquisition. Plaintiff sought, among
other things: to enjoin the consummation of the Acquisition; to require that the
Company make additional disclosures to its stockholders in connection with the
Acquisition; damages in unspecified amounts; and costs, disbursements and
counsel and expert fees. An agreement in principle was reached to settle this
action. The plaintiff withdrew his application for a preliminary injunction.
The Acquisition was approved by the Company's stockholders at the Annual Meeting
of Stockholders on September 8, 1997, and the Acquisition was consummated on
September 11, 1997. A definitive Stipulation of Settlement has been executed.
The Stipulation of Settlement is subject to approval by the Delaware Court of
Chancery.
Robert L. Piccioni, a former director of the Company, and Joan Piccioni, the
former President of the Company's Dove Medical Systems, Inc. ("Dove")
subsidiary, filed suit against the Company and Norland Corporation in the United
States District Court for the Central District of California on October 9, 1997.
The action was commenced shortly after the Company made claims for
indemnification from Dr. and Mrs. Piccioni and certain other former stockholders
of Dove in connection with the Company's acquisition of Dove in April of 1996.
The Piccionis allege breach of contract and fraud by the Company in connection
with the acquisition of Dove, claim they suffered damages in excess of
$2,500,000 and seek the release of the portion of the purchase price paid for
Dove that is held in escrow to be available to satisfy indemnity obligations of
the Piccionis and such other former stockholders of Dove to the Company. The
Company believes that this action is without merit and, accordingly, believes
that there will be no adverse material effect on the Company's results of
operations, cash flows or financial position.
-11-
<PAGE>
Notes to Condensed Consolidated Financial Statements, continued:
(9) FUTURE IMPACT OF RECENT ACCOUNTING PRONOUNCEMENTS
Statement of Financial Accounting Standards No. 128 "Earnings Per Share" changes
the reporting requirements for earnings per share (EPS) for publicly traded
companies by replacing primary EPS with basic EPS and changing the disclosures
associated with this change. The Company is required to adopt this standard in
the fourth quarter of 1997 and does not expect a material impact on its per
share results from the implementation of this standard.
Statement of Financial Accounting Standards No. 130 "Reporting Comprehensive
Income" requires that comprehensive income and its components be reported in the
financial statements. The Company is required to adopt this standard in 1998
and is currently evaluating this standard.
Statement of Financial Accounting Standards No. 131 "Disclosures About Segments
of an Enterprise and Related Information" requires that publicly traded
companies report financial and descriptive information about its reportable
operating segments. The Company is required to adopt this standard in 1998 and
anticipates that the adoption of this standard will not have an effect on the
current presentation of such information.
-12-
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
THE FOLLOWING DISCUSSION OF THE FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF
THE COMPANY SHOULD BE READ IN CONJUNCTION WITH THE FINANCIAL STATEMENTS AND THE
RELATED NOTES THERETO INCLUDED ELSEWHERE IN THIS REPORT. THE FOLLOWING
DISCUSSION CONTAINS FORWARD-LOOKING STATEMENTS WHICH INVOLVE RISKS AND
UNCERTAINTIES, SOME OF WHICH ARE DESCRIBED IN THE INTRODUCTION TO THE COMPANY'S
ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 1996. SUCH
INTRODUCTION IS INCORPORATED HEREIN BY REFERENCE. THE COMPANY'S ACTUAL RESULTS
COULD DIFFER MATERIALLY FROM THOSE ANTICIPATED IN THESE FORWARD-LOOKING
STATEMENTS AS A RESULT OF CERTAIN FACTORS.
RESULTS OF OPERATIONS
Revenue for the three months ended September 30, 1997 decreased $1,706,345
(21.2%) to $6,360,537 from $8,066,882 for the comparable period of 1996.
Revenue for the nine months ended September 30, 1997 decreased $742,842 (3.7%)
to $19,491,446 from $20,234,288 for the comparable period in 1996. The decrease
in sales for the third quarter of 1997 compared to the third quarter of 1996 was
largely a result of a decrease in sales in the Pacific Rim and the United
States, offset by an increase in sales to Europe and Latin America. The
decrease in sales for the nine months ended September 30, 1997 as compared to
sales for the nine month period in 1996 was largely a result of a decrease in
sales in the Pacific Rim and to Japan in particular, offset by increases in
sales to the United States (for the first six months), Europe and Latin America.
Sales in the United States have been affected by Medicare reimbursement rates,
as discussed below. Sales in Japan declined due in part to increased
competition, reductions in reimbursement for certain densitometry tests in Japan
and the effects of operational difficulties experienced with pDEXA units during
part of 1996. The Company believes that these operational difficulties have
been addressed. Sales in the United States and Japan represented 86.0% and
2.4%, respectively, of total revenue for the three months ended September 30,
1997 and 71.2% and 10.1%, respectively, of total revenue for the three months
ended September 30, 1996. Sales in the United States and Japan represented
77.9% and 2.0%, respectively, of total revenue for the nine months ended
September 30, 1997, and 50.5% and 28.0%, respectively, of total revenue for the
nine months ended September 30, 1996. Sales of complete bone densitometry
systems represented 90.3% and 95.1% of total revenue for the three months ended
September 30, 1997 and 1996, respectively, and 91.2% and 94.2% of total revenues
for the nine months ended September 30, 1997 and 1996, respectively. Sales of
parts and services and rental income comprised the balance of revenues for such
periods.
Revenues have been affected by changes in the Medicare reimbursement rates for
bone densitometry tests. In November 1996 the Health Care Financing
Administration (HCFA) announced changes for 1997 that significantly reduced the
reimbursement rate for peripheral bone densitometry tests. The Company reduced
the price of its pDEXA peripheral systems in the fourth quarter of 1996, and
since that time, the mix of the Company's product revenue has
-13-
<PAGE>
changed. A majority of the Company's revenues in 1997 has been derived from
sales of the larger Eclipse and XR36 systems for which the Medicare
reimbursement rate was not significantly reduced, as compared to the pDEXA
system. In June 1997 HCFA published proposed changes for 1998 that would have
increased the reimbursement rate for peripheral systems and significantly
reduced the rate for the larger systems. Sales of the Company's peripheral
systems increased significantly in the quarter ended September 30, 1997, and
sales of the larger systems declined. The increased sales of the lower priced
peripheral systems did not fully compensate for the revenue loss resulting from
the decreased sales of the larger systems. HCFA recently announced the final
reimbursement rates for 1998. The rate for peripheral DXA tests was increased
by an amount in excess of the increase proposed in June. The proposed
significant reduction in the rate for the larger systems was not adopted.
Instead, the rate was increased by approximately 9% over the 1997 rate.
Revenues and the mix of products sold are expected to continue to be influenced
by the relative degree of difference in reimbursement rate levels for peripheral
systems. They will also be influenced by the Company's ability to bring to the
market lower cost peripheral systems that can be operated more profitably by end
users at the applicable reimbursement rates.
Cost of revenue as a percentage of revenue was 46.9% and 67.1% for the three
months ended September 30, 1997 and 1996, respectively, resulting in a gross
margin of 53.1% for the three months ended September 30, 1997 compared to 32.9%
for the comparable period of 1996. Cost of revenue as a percentage of revenue
was 53.4% and 65.3% for the nine months ended September 30, 1997 and 1996,
respectively, resulting in a gross margin of 46.6% for the nine months ended
September 30, 1997 compared to 34.7% for the comparable period of 1996. The
increase in gross margin is primarily attributed to the impact of price
reductions under the Distribution Agreement with Norland Corporation and Stratec
Medizintechnik GmbH which became effective during the fourth quarter of 1996 and
the Company's acquisition of Norland Corporation on September 11, 1997,
following which the Company received the entire margin on systems manufactured
by Norland Corporation.
Sales and marketing expense increased $574,032 (61.0%) to $1,515,775 for the
three months ended September 30, 1997 from $941,743 for the three months ended
September 30, 1996, and increased as a percentage of revenue to 23.8% from
11.7%. Sales and marketing expense increased $1,795,859 (74.8%) to $4,196,122
for the nine month period ended September 30, 1997 from $2,400,263 for the nine
months ended September 30, 1996, and increased as a percentage of revenue to
21.5% from 11.9%. The dollar increases were primarily due to increased expenses
of new sales and marketing personnel, the cost of expanded marketing efforts,
and increased expenses related to customer service.
General and administrative expense increased $267,868 (53.8%) to $765,574 for
the three months ended September 30, 1997 from $497,706 for the three months
ended September 30, 1996 and increased as a percentage of revenue to 12.0% from
6.2%. General and administrative expense increased $695,713 (53.9%) to
$1,986,856 for the nine month period ended September 30, 1997 from $1,291,143
for the nine months ended September 30, 1996, and increased as a
-14-
<PAGE>
percentage of revenue to 10.2% from 6.4%. The dollar increases were primarily
due to expenses of new personnel and increased expenses of existing personnel
and professional fees.
Research and development expense increased $70,906 (75.0%) to $165,502 for the
three months ended September 30, 1997 from $94,596 for the three months ended
September 30, 1996, and also increased as a percentage of revenue to 2.6% from
1.2%. Research and development expense increased $152,358 (75.8%) to $353,289
for the nine months ended September 30, 1997 from $200,931 for the nine months
ended September 30, 1996, and also increased as a percentage of revenue to 1.8%
from 1.0%. The dollar increases are primarily the result of the inclusion of
research and development expenses of Norland Corporation following the Company's
acquisition of Norland Corporation on September 11, 1997.
The Company recognized non-recurring charges of $18,462,540 and $397,697 in the
three months ended September 30, 1997 and 1996, respectively. For the three
months ended September 30, 1997, the following non-recurring charges were taken.
In connection with the acquisition of Norland Corporation, certain research and
development projects acquired were not at a stage in which technological
feasibility had been achieved and were determined to have no alternative future
use. Accordingly, $7,900,000 of the purchase price was allocated to this
in-process research and development and expensed. With the acquisition of
Norland Corporation, including its ongoing research and development projects,
management determined that the Company's inventory of bone densitometers used
for demonstration and customer service purposes had no future value and
recognized a $1,460,375 non-recurring charge for their write-off. In response
to the increasing dominance of the peripheral bone densitometry market by DXA
technology, the Company closed the Newbury Park facility of its Dove Medical
Systems subsidiary and recorded a $9 million write-off of inventories, fixed
assets, goodwill, a patent and other intangible assets, having concluded that
expected cash flows will not enable the Company to recover any of the remaining
carrying value. In August 1997, the Company acquired distribution rights to an
ultrasound product developed by IMRO Inc. and recorded a $101,805 non-recurring
charge for costs incurred in connection with the selection of an ultrasound
product. In the quarter ended September 30, 1996, the Company recorded a
non-recurring stock offering charge of $397,697 in connection with a withdrawn
stock offering.
Interest expense of $66,096 for the three months ended September 30, 1997
represents interest on the Purchase Note issued by the Company in connection
with the acquisition of Norland Corporation on September 11, 1997. Interest
income in the three and nine month periods ended September 30, 1997 and 1996
consisted primarily of interest earned on the proceeds of the Company's initial
public offering and on other cash and loan balances, reduced by other expenses
consisting primarily of bank charges and other fees related to bank transfers.
The decrease in interest income in the three and nine month periods ended
September 30, 1997 as compared to September 30, 1996 reflects reduced interest
income resulting from utilization of such offering proceeds.
-15-
<PAGE>
The Company recognized an income tax benefit for the three and nine months ended
September 30, 1997 as a result of the tax benefit derived from certain of the
non-recurring charges recorded during the quarter ended September 30, 1997. No
deferred tax valuation allowance is deemed necessary as a result of management's
evaluation that all of the deferred tax assets will be realized.
The Company had a net loss of $15,466,142 ($2.15 per share) for the three months
ended September 30, 1997 compared to net income of $515,335 ($0.07 per share)
for the three months ended September 30, 1996. The Company had a net loss of
$14,361,386 ($2.00 per share) for the nine months ended September 30, 1997
compared to net income of $1,956,647 ($0.27 per share) for the nine months ended
September 30, 1996. The non-recurring charges of $18,462,540 ($2.23 per share)
recognized in the quarter ended September 30, 1997 reduced net income on an
after tax basis by $16,025,926. Excluding the after tax effect of this charge,
net income for the quarter ended September 30, 1997 would be $559,784 ($0.08 per
share) and net income for the nine months ended September 30, 1997 would be
$1,665,073 ($0.23 per share), representing decreases of 25.5% and 24.1%,
respectively, over the comparable periods in 1996 (also excluding the 1996
non-recurring charge).
LIQUIDITY AND CAPITAL RESOURCES
At December 31, 1996, the Company had cash of $8,133,468 and a $1,949,039 U.S.
Treasury bill. The Treasury bill was converted to cash during the quarter ended
June 30, 1997. At September 30, 1997, the Company had cash of $2,385,127. The
decrease in cash was primarily the result of increased accounts receivable,
decreased accounts payable, increased inventories, and costs related to the
acquisition of Norland Corporation, including the $1,250,000 payment made at
closing.
The Company's accounts receivable increased 48.3% to $13,615,546 at September
30, 1997 from $9,182,488 at December 31, 1996, which reflects less prompt
payment by the Company's customers. At September 30, 1997, the two largest
balances, 20.1% and 9.8% of total outstanding trade receivables, were owed by
two U.S. distributors.
Property and equipment as of September 30, 1997 consisted of computer and
telephone equipment, a management information system, office furniture and
improvements to leased facilities. At the present time, no significant
expenditures for additional equipment or systems are planned.
On March 11, 1998 the Company will be obligated to make a $1,250,000 principal
payment on the Purchase Note issued as part of the purchase price for Norland
Corporation. Interest payments will range from approximately $265,000 to
$300,000 per quarter, depending upon the final amount of the purchase price.
-16-
<PAGE>
The Company's operations have been financed primarily by cash flow from
operations and the proceeds of its initial public offering. The Company plans
to finance its operations for the next twelve months from its current cash
position and cash flow from operations, as well as from other sources, including
borrowing arrangements and/or proceeds of stock offerings. In addition, the
nature of the Company's business is such that it is subject to changes in
technology, government approval and regulation, and changes in third-party
reimbursement in the United States and numerous foreign markets. Significant
changes in one or more of these factors in a major market for the Company's
products could significantly affect the Company's cash needs.
-17-
<PAGE>
NORLAND MEDICAL SYSTEMS, INC.
PART II OTHER INFORMATION
Item 1. LEGAL PROCEEDINGS
IRWIN I. MILLER V. REYNALD G. BONMATI ET AL., DEFENDANTS, AND NORLAND
MEDICAL SYSTEMS, INC., NOMINAL DEFENDANT.
This action relates to the acquisition of Norland Corporation by the
Company. The commencement of this action in the Delaware Court of
Chancery was reported in the Company's Form 8-K filed August 8, 1997.
The Company's Form 10-Q for the quarter ended June 30, 1997 reported
that an agreement in principle had been reached to settle the action
and that the plaintiff had withdrawn his application for a preliminary
injunction against the acquisition. The acquisition was approved by
the Company's stockholders at the Annual Meeting of Stockholders on
September 8, 1997, and the acquisition was consummated on September
11, 1997. A definitive Stipulation of Settlement has been executed.
The terms of the settlement are the same as those of the agreement in
principle that were summarized in the Company's Supplement to Proxy
Statement dated August 28, 1997, including the payment by the Company
of any award of fees and expenses of plaintiff's counsel up to
$250,000. The Stipulation of Settlement is subject to approval by the
Delaware Court of Chancery.
ROBERT L. PICCIONI, PH.D. AND JOAN PICCIONI V. NORLAND MEDICAL
SYSTEMS, INC. AND NORLAND CORP.
Robert L. Piccioni, a former director of the Company, and Joan
Piccioni, the former President of the Company's Dove Medical Systems,
Inc. ("Dove") subsidiary, filed suit against the Company and Norland
Corporation in the United States District Court for the Central
District of California on October 9, 1997. The action was commenced
shortly after the Company made claims for indemnification from Dr. and
Mrs. Piccioni and certain other former stockholders of Dove in
connection with the Company's acquisition of Dove in April of 1996.
The Piccionis allege breach of contract and fraud by the Company in
connection with the acquisition of Dove, claim they suffered damages
in excess of $2,500,000 and seek the release of the portion of the
purchase price paid for Dove that is held in escrow to be available to
satisfy indemnity obligation of the Piccionis and such other former
stockholders of Dove to the Company. The Company believes that the
Piccionis' action is without merit.
-18-
<PAGE>
Item 2. CHANGE IN SECURITIES
On September 8, 1997, the Company's stockholders approved an amendment
to the Company's Restated Certificate of Incorporation increasing the
number of authorized shares of Common Stock, par value $.0005 per
share, from 10,000,000 to 20,000,000. A Certificate of Amendment
effecting such change was filed with the Secretary of State of
Delaware on October 24, 1997.
Item 3. DEFAULTS UPON SENIOR SECURITIES
None
Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
(a) The Annual Meeting of Stockholders of Norland Medical Systems,
Inc. was held on September 8, 1997.
(b) The following persons were elected as directors of the Company at
the Annual Meeting: Reynald G. Bonmati, James J. Baker, Michael
W. Huber, Andre-Jacques Neusy and Albert S. Waxman.
(c) The following matters were voted on at the Annual Meeting:
(1) The proposal to approve the acquisition of Norland
Corporation was approved as follows: 5,660,994 shares for
(including 2,360,994 shares held by stockholders other than
Reynald G. Bonmati, Hans Schiessl, Norland Partners, L.P.,
and Novatech Ventures, L.P.); 158,623 shares against; 10,946
shares abstaining; and 879,761 shares broker non-votes.
(2) The proposal to elect the five persons named in Item 4(b) as
directors of the Company for the ensuing year was approved
as follows: 6,525,051 shares in favor of Mr. Bonmati and
6,529,029 shares in favor of each of the other candidates;
185,273 shares withheld for Mr. Bonmati and 181,295 shares
withheld for each of the other candidates; and no broker
non-votes.
(3) The proposal to approve an amendment to the Company's
Restated Certificate of Incorporation increasing the amount
of authorized Common Stock was approved as follows:
6,530,088 shares for; 168,250 shares against; 11,896 shares
abstaining; and no broker non-votes.
-19-
<PAGE>
(4) The proposal to approve and adopt amendments to the
Company's Amended and Restated 1994 Stock Option and
Incentive Plan was approved as follows: 4,236,431 shares
for; 1,821,177 shares against; 5,750 shares abstaining; and
646,956 shares broker non-votes.
(5) The proposal to ratify the selection of Coopers & Lybrand
L.L.P. as the Company's independent auditors for 1997 was
approved as follows: 6,596,201 shares for; 127,473 shares
against; 6,650 shares abstaining; and no broker non-votes.
Item 5. OTHER INFORMATION
None
Item 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits furnished:
3.1 Restated Certificate of Incorporation of Norland Medical
Systems, Inc., as amended on October 24, 1997
11 Statement Regarding Computation of Earnings per Share
27 Financial Data Schedule
(b) Reports on Form 8-K:
The Company filed a report on Form 8-K on August 8, 1997
reporting commencement of the litigation referred to in Item 1
above with respect to the proposed acquisition of Norland
Corporation.
The Company filed a report on Form 8-K on September 24, 1997
reporting the consummation of the Company's acquisition of
Norland Corporation.
-20-
<PAGE>
NORLAND MEDICAL SYSTEMS, INC.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
NORLAND MEDICAL SYSTEMS, INC.
(Registrant)
Date: November 13, 1997 /s/ Reynald G. Bonmati
----------------------------------------
Reynald G. Bonmati
President
Date: November 13, 1997 /s/ Kurt W. Streams
----------------------------------------
Kurt W. Streams
Vice President, Finance
(Principal Financial and Accounting
Officer)
-21-
<PAGE>
NORLAND MEDICAL SYSTEMS, INC.
EXHIBIT INDEX
Number Description
- ------ -----------
3.1 Restated Certificate of Incorporation of Norland Medical Systems,
Inc., as amended on October 24, 1997
11 Statement Regarding Computation of Earnings Per Share
27 Financial Data Schedule
-22-
<PAGE>
EXHIBIT 3.1
RESTATED CERTIFICATE OF
INCORPORATION OF
NORLAND MEDICAL SYSTEMS, INC.
----------------------
Under Section 245
of the
General Corporation Law of the State of Delaware
----------------------
The undersigned, Vice President and Secretary of NORLAND MEDICAL
SYSTEMS, INC., a corporation organized and existing under and by virtue of the
General Corporation Law of the State of Delaware (the "Corporation"), do hereby
certify:
A. The name of the Corporation is NORLAND MEDICAL SYSTEMS, INC.
B. The Original Certificate of Incorporation of the Corporation was filed
by the Secretary of the State of Delaware on the 21st day of December, 1993,
under the name Ostech, Inc.
C. The restatement of the Certificate of Incorporation set forth herein,
in accordance with the provisions of Section 245 of the General Corporation Law
of the State of Delaware, merely restates and integrates and does not further
amend the provisions of the Certificate of Incorporation of NORLAND MEDICAL
SYSTEMS, INC. as theretofore amended or supplemented and there is no discrepancy
between those provisions and the provisions of the Restated Certificate of
Incorporation setforth herein. This Restated Certificate of Incorporation was
duly adopted by the Board of Directors of the Corporation at a meeting, duly
called and
<PAGE>
held, in accordance with the provisions of Section 245 of the General
Corporation law of the State of Delaware.
D. The Certificate of Incorporation of the Corporation is hereby
restated to set forth its entire terms as follows:
RESTATED
CERTIFICATE OF INCORPORATION
OF
NORLAND MEDICAL SYSTEMS, INC.*
FIRST: The name of the corporation is NORLAND MEDICAL SYSTEMS,
INC.
SECOND: The address of the registered office of the Corporation
in the State of Delaware is 1209 Orange Street, City of Wilmington, County
of New Castle. The name of the registered agent of the Corporation at such
address is The Corporation Trust Company.
THIRD: The purpose of the Corporation is to engage in any
lawful act or activity for which corporations may be organized under the
General Corporation Law of the State of Delaware.
FOURTH: The total number of shares of all classes of capital
stock which the Corporation shall have authority to issue is twenty-one
million (21,000,000) shares, consisting of the following classes of stock:
(A) one million (1,000,000) shares of Preferred Stock, par value $.0005 per
share ("Preferred Stock"); and (B) twenty million (20,000,000) shares of
Common Stock, par value $.0005 ("Common Stock").
The designations, powers, preferences and relative, participating,
optional and other special rights and the qualifications, limitations and
restrictions thereof in respect of the Preferred Stock and the Common Stock
are as follows:
_________________
* Conformed to give effect to Certificate of Amendment filed with the Secretary
of State of Delaware on October 24, 1997.
2
<PAGE>
(1) PREFERRED STOCK
Preferred Stock may be issued from time to time in one or more
series, each such series to have such terms as stated or expressed in the
resolution or resolutions providing for the issue of such series adopted by
the Board of Directors of the Corporation as hereinafter provided. Any
shares of Preferred Stock which may be redeemed, purchased or acquired by
the Corporation may be reissued except as otherwise provided by law or by
action of the Board of Directors. Different series of Preferred Stock
shall not be construed to constitute different classes of shares for the
purpose of voting by classes unless expressly provided.
Authority is hereby expressly granted to the Board of Directors
from time to time to issue Preferred Stock in one or more series, and in
connection with the creation of any such series, by resolution or
resolutions providing for the issue of shares thereof, to determine and fix
such voting powers, full or limited, or no voting powers, and such
designations, preferences and relative participating, optional or other
special rights, and qualifications, limitation or restrictions thereof,
including without limitations thereof, dividend rights, conversion rights,
redemption privileges and liquidation preferences, as shall be stated and
expressed in such resolutions, all to the full extent now or hereafter
permitted by the General Corporation Law of Delaware. Without limiting the
generality of the foregoing, the resolutions providing for the issuance of
any series of Preferred Stock may provide that such series shall be
superior or rank equally or be junior to the Common Stock or any other
series of Preferred Stock. No vote of the holders of the Common Stock or
Preferred Stock shall, unless otherwise provided herein or in the
resolutions creating any particular series of Preferred Stock, be a
prerequisite to the issuance of any shares of any series of Preferred Stock
authorized by and complying with the conditions of this Certificate of
Incorporation.
(2) COMMON STOCK
Subject to the rights of the holders of the Preferred Stock, the
Common Stock shall be entitled to dividends out of funds legally available
therefor, when, as and if declared and paid to the holders of Common Stock,
and upon liquidation of the Corporation to share ratably in the assets of
the Corporation available for distribution to the holders of Common Stock.
Except as otherwise provided herein or by law, the holders of Common Stock
shall have full voting rights and powers and each share of Common Stock
shall be entitled to one vote.
FIFTH: The Board of Directors is expressly authorized to
adopt, amend or repeal By-Laws, subject to the reserved power of the
stockholders to amend and repeal any By-Laws adopted by the Board of
Directors.
3
<PAGE>
SIXTH: Unless and except to the extent that the By-Laws shall
so require, the election of directors of the Corporation need not be by
written ballot.
SEVENTH: Whenever a compromise or arrangement is proposed
between this Corporation and its creditors or any class of them and/or
between this Corporation and its stockholders or any class of them, any
court of equitable jurisdiction within the State of Delaware may, on the
application in a summary way of this Corporation or of any creditor or
stockholder thereof, or on the application of any receiver or receivers
appointed for this Corporation under Section 291 of Title 8 of the Delaware
Code or on the application of trustees in dissolution or of any receiver or
receivers appointed for this Corporation under Section 279 of Title 8 of
the Delaware Code, order a meeting of the creditors or class of creditors,
and/or of the stockholders or class of stockholders of this Corporation, as
the case may be, to be summoned in such manner as the said court directs.
If a majority in number representing three-fourths in value of the
creditors or class of creditors, and/or of the stockholders or class of
stockholders of this Corporation, as the case may be, agree to any
compromise or arrangement and to any reorganization of this Corporation as
a consequence of such compromise or arrangement, the said compromise or
arrangement and the said reorganization shall, if sanctioned by the court
to which the said application has been made, be binding on all the
creditors or class of creditors, and/or on all the stockholders or class of
stockholders, of this Corporation, as the case may be, and also on this
Corporation.
EIGHTH: No person who is or was a director of the Corporation
shall be personally liable to the Corporation for monetary damages for
breach of fiduciary duty as a director unless, and only to the extent that,
such director is liable (i) for any breach of the director's duty of
loyalty to the Corporation or its stockholders, (ii) for acts or omissions
not in good faith or which involve intentional misconduct or a knowing
violation of law, (iii) under Section 174 of the General Corporation Law of
the State of Delaware or any amendment thereto or successor provision
thereto, or (iv) for any transaction from which the director derived an
improper personal benefit. No amendment to, repeal or adoption of any
provision of the Certificate of Incorporation inconsistent with this
article shall apply to or have any effect on the liability of any director
of the Corporation for or with respect to any acts or omissions of such
director occurring prior to such amendment, repeal, or adoption of an
inconsistent provision.
NINTH: Any and all right, title, interest and claim in or to
any dividends declared by the Corporation, whether in cash, stock or
otherwise, which are unclaimed by the stockholder entitled thereto for a
period of six (6) years after the close of business on the payment date,
shall be and be deemed to be extinguished and abandoned, and such unclaimed
dividends in the possession of the Corporation, its transfer agents or
other agents or depositaries, shall at such time become the absolute
4
<PAGE>
property of the Corporation, free and clear of any and all claims of any
persons whatsoever.
IN WITNESS WHEREOF, the undersigned, Vice President and Secretary
of NORLAND MEDICAL SYSTEMS, INC., hereunto sign our names and affirm that
the statements made herein are true under the penalties of perjury, this
12th day of October, 1995.
/s/ Ralph G. Theodore
------------------------------
Ralph G. Theodore
Vice President
Attest: /s/ John W. Buckman
------------------------------
John W. Buckman
Secretary
5
<PAGE>
NORLAND MEDICAL SYSTEMS, INC. EXHIBIT 11
Statement Regarding Computation of Earnings Per Share
(Unaudited)
PRIMARY BASIS THREE MONTHS ENDED SEPTEMBER 30
-------------------------------
1997 1996
---- ----
Net income (loss) $(15,466,142) $ 515,335
Weighted average shares
outstanding 7,154,161 6,895,781
Stock options 90,845 319,139
Weighted average number of
common and common equivalent
shares outstanding 7,245,006 7,214,920
Earnings (loss) per share $ (2.13) $ 0.07
PRIMARY BASIS NINE MONTHS ENDED SEPTEMBER 30
------------------------------
1997 1996
---- ----
Net income (loss) $(14,361,386) $1,956,647
Weighted average shares
outstanding 7,154,161 6,706,326
Stock options 48,787 469,735
Weighted average number of
common and common equivalent
shares outstanding 7,202,948 7,176,061
Earnings (loss) per share $ (1.99) $ 0.27
<PAGE>
NORLAND MEDICAL SYSTEMS, INC.
Statement Regarding Computation of Earnings Per Share
(Unaudited)
FULLY DILUTED BASIS THREE MONTHS ENDED SEPTEMBER 30
-------------------------------
1997 1996
---- ----
Net income (loss) $(15,466,142) $ 515,335
Weighted average shares
outstanding 7,140,071 6,895,781
Stock options 51,146 365,723
Weighted average number of
common and common equivalent
shares outstanding 7,191,218 7,261,504
Earnings (loss) per share $ (2.15) $ 0.07
FULLY DILUTED BASIS NINE MONTHS ENDED SEPTEMBER 30
------------------------------
1997 1996
---- ----
Net income (loss) $(14,361,386) $1,956,647
Weighted average shares
outstanding 7,140,071 6,706,326
Stock options 53,237 497,064
Weighted average number of
common and common equivalent
shares outstanding 7,193,309 7,203,390
Earnings (loss) per share $ (2.00) $ 0.27
-2-
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
Condensed Financial Statements and is qualified in its entirety by reference to
such financial statements.
</LEGEND>
<MULTIPLIER> 1
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-END> SEP-30-1997
<CASH> 2,385,127
<SECURITIES> 0
<RECEIVABLES> 14,112,747
<ALLOWANCES> 250,000
<INVENTORY> 3,123,377
<CURRENT-ASSETS> 22,136,283
<PP&E> 2,155,613
<DEPRECIATION> 1,451,715
<TOTAL-ASSETS> 33,380,973
<CURRENT-LIABILITIES> 6,611,922
<BONDS> 14,279,344
0
0
<COMMON> 3,578
<OTHER-SE> 12,193,543
<TOTAL-LIABILITY-AND-EQUITY> 33,380,973
<SALES> 18,632,127
<TOTAL-REVENUES> 19,491,446
<CGS> 10,412,167
<TOTAL-COSTS> 10,412,167
<OTHER-EXPENSES> 24,998,807
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 66,096
<INCOME-PRETAX> (15,659,386)
<INCOME-TAX> (1,298,000)
<INCOME-CONTINUING> (14,361,386)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (14,361,386)
<EPS-PRIMARY> (1.99)
<EPS-DILUTED> (2.00)
</TABLE>
